2026-08-29T17:25:33Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/185212024-09-21T21:16:19Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Fernandez Rivera, Constantino
author
Calvo Rodríguez, María
author
Poveda, José Luís
author
Pascual, Julio
author
Crespo, Marta
author
Gomez, Gonzalo
author
Cabello Pelegrin, Sheila
author
Paul, Javier
author
Lauzurica, Ricardo
author
Perez Mir, Mònica
author
Moreso, Francesc
author
Perelló, Manel
author
Andres, Amado
author
González, Esther
author
Fernandez, Ana
author
Mendiluce, Alicia
author
Fernández Carbajo, Beatriz
author
Sanchez Fructuoso, Ana
author
Calvo, Natividad
author
Suarez, Alejandro
author
Bernal Blanco, Gabriel
author
Osuna, Antonio
author
Ruiz-Fuentes, M Carmen
author
Melilli, Edoardo
author
Montero Perez, Nuria
author
Ramos, Ana
author
Fernández, Beatriz
author
López, Verónica
author
Hernandez, Domingo
author
Better study
2024-02-19T15:32:25Z
2024-02-19T15:32:25Z
2021-12-17
10.1111/ctr.14550
1399-0012
Clinical transplantation
http://hdl.handle.net/10668/19932
34851532
http://hdl.handle.net/20.500.12105/18521
Multicenter, prospective, observational study to compare the relative bioavailability of once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus-based regimen were included 14 days post-transplant and followed up for 6 months. Data from 218 participants were evaluated: 129 in the LCPT group (Envarsus) and 89 in the PR-Tac (Advagraf) group. Patients in the LCPT group exhibited higher relative bioavailability (Cmin /total daily dose [TDD]) vs. PR-Tac (61% increase; P
eng
bioavailability
clinical practice
pharmacokinetics
renal transplantation
tacrolimus
treatment failure
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
research article